Source: Annual Congress 2010 - Pathology of lung cancer



Rating:

Share or cite this content

Citations should be made in the following way:
L. Zambon, H. Honma, G. Lourenço, I. Saad, R. Mussi, C. Lima (Brazil). D104N poluymorphism in endostatin, an angiogenesis inhibitor, in lung cancer susceptibility. Eur Respir J 2010; 36: Suppl. 54, 3263

Member's Comments

No comment yet.

Related content which might interest you: Novel anti-angiogenic pharmacotherapy strategies Source: Annual Congress 2005 - Update on the role of angiogenesis in the pathogenesis and treatment of lung diseases Year: 2005 Tumor-related angiogenesis: role in tumour growth and metastasis formation Source: Annual Congress 2005 - Update on the role of angiogenesis in the pathogenesis and treatment of lung diseases Year: 2005 Adipocyte-derived exosomes promote lung cancer metastasis byincreasing MMP9 activity via transferring MMP3 to lung cancer cells Source: International Congress 2017 – Basic research in lung cancer: a scientific potpourri from genetic alterations to immune cells Year: 2017 The biology of lung cancer Source: ISSN=1025-448x, ISBN=1-904097-18-9, page=61 Year: 2001 Increased vascular-endothelial growth factor a (VEGF-A) expression and response to angiogenesis inhibitor erlotinib in non-small-cell lung cancer (NSCLC) – hint for a new predictive marker? Source: Annual Congress 2007 - Therapeutic approaches in thoracic oncology Year: 2007 Markers of angiogenesis in serum are correlating with disease progress in lung cancer Source: Annual Congress 2006 - Prognostic factors in lung cancer Year: 2006 Tissue inhibitors of metalloproteinase-2 C-303T and G-418C genetic polymorphisms are associated with an increased risk of non-small cell lung cancer in Taiwan Source: Annual Congress 2008 - Biology in thoracic tumours Year: 2008 The association of MMP-7 and MMP-13 genetic polymorphisms with susceptibility to non-small cell lung cancer in Taiwan Source: Annual Congress 2008 - Biology in thoracic tumours Year: 2008 Anti-angiogenic strategies and vascular targeting in the treatment of lung cancer Source: Eur Respir J 2002; 19: 557-570 Year: 2002 A novel biologic classification of non-small cell lung cancer Source: Annual Congress 2005 - New insights into prognosis in thoracic surgical oncology Year: 2005 Diverse effects of PAI-1 proteins on lung and prostate cancer cell invasion Source: Annual Congress 2011 - Lung development and neoplasia Year: 2011 Proteinase inhibition regulates the anti-tumor activity of PAI-1 towards lung and prostate cancer cells Source: Annual Congress 2011 - Lung cancer: molecular pathology and functional genomics Year: 2011 Predicting activity of EGFR (epidermal growth factor receptor) inhibitors in diffuse bronchiolo-alveolar carcinoma or so-called pneumonic adenocarcinoma Source: Annual Congress 2006 - Bronchiolo-alveolar carcinoma Year: 2006 Association of polymorphism of the human nm23-H1 gene (NME1) with susceptibility to and severity of non-small cell lung cancer Source: Annual Congress 2007 - Diagnosis and prognosis in thoracic oncology Year: 2007 The effect of SDF-1/CXCR4 on expression of VEGF and MMP-9 in small cell lung cancer Source: Annual Congress 2012 - New aspects of lung cancer biology Year: 2012 Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation Source: Eur Respir J 2011; 37: 624-631 Year: 2011 The effect of matrix metalloproteinase-9 and vascular endothelial growth factor expression on survival of non-small cell lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 324s Year: 2005 ABCG2 is determinant to SN-38 resistance in non-small cell lung cancer Source: Annual Congress 2005 - Prognostic factors in lung cancer Year: 2005 Macrophage expression of interleukin-10 is a prognostic factor in nonsmall cell lung cancer Source: Eur Respir J 2007; 30: 627-632 Year: 2007 Efficacy of Afatinib, Erlotinib, and Gefitinib on epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) patients with brain metastasis: a network meta-analysis Source: International Congress 2018 – Lung cancer: modern therapies and beyond Year: 2018